Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS H HERFARTH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1538246574
CMS profile
748946
Location
CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$13,500.00

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $13,500.00 6

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $9,750.00 3
Eli Lilly and Company $3,600.00 2
Biogen, Inc. $150.00 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS H HERFARTH

NPI 1538246574 · CMS profile ID 748946

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $13,500.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $2,800.0008/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186654843 CMS
Gilead Sciences, Inc. $2,850.0006/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351494 CMS
Biogen, Inc. $150.0005/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208351752 CMS
Gilead Sciences, Inc. $4,500.0002/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351060 CMS
Eli Lilly and Company $800.0001/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186654845 CMS
Gilead Sciences, Inc. $2,400.0001/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351666 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,664.39 10
PY2020 $19,041.44 14
PY2021 $7,950.00 5
PY2022 $5,950.00 3
PY2023 $3,236.00 3
PY2024 $17,266.46 16
PY2025 $13,500.00 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,575.00 2
PY2025 Principal investigator $12,323.55 21
PY2024 Recipient $319,533.00 4
PY2024 Principal investigator $59,545.89 24
PY2023 Principal investigator $224,917.53 43
PY2022 Principal investigator $370,819.65 53
PY2021 Principal investigator $392,748.05 56
PY2020 Principal investigator $481,918.70 51
PY2019 Recipient $4,200.00 1
PY2019 Principal investigator $373,860.96 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,465.60 12/22/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890369795
Principal investigator 1 ABBVIE INC. $6,649.60 12/19/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890370025
Principal investigator 1 ABBVIE INC. $200.00 12/08/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890369517
Principal investigator 1 ABBVIE INC. $4,165.12 12/01/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890369793
Principal investigator 1 Roche Products Limited $921.60 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950701263
Principal investigator 1 ABBVIE INC. $3,264.00 11/09/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890368581
Principal investigator 1 ABBVIE INC. $23,285.80 11/09/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890368583
Principal investigator 1 ABBVIE INC. $2,219.52 10/06/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890368579
Principal investigator 1 ABBVIE INC. $1,350.40 09/29/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890367495
Principal investigator 1 ABBVIE INC. $13,173.44 09/15/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890366565
Principal investigator 1 Roche Products Limited $460.80 09/13/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950725543
Principal investigator 1 ABBVIE INC. $460.80 09/08/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890366635
Principal investigator 1 ABBVIE INC. $1,350.40 08/30/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890367493
Principal investigator 1 Novo Nordisk Inc $7,097.40 08/23/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
Efficacy of GLP-1 receptor agonist therapy in patients with an ileal -pouch anal anastomosis (IPAA) No dispute reported 06/30/2026 897304881
Principal investigator 1 Roche Products Limited $1,940.00 08/16/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950725547
Principal investigator 1 ABBVIE INC. $5,252.48 08/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890366603
Principal investigator 1 Genentech, Inc. $81.00 08/09/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950725553
Principal investigator 1 ABBVIE INC. $850.00 08/03/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890367491
Principal investigator 1 ABBVIE INC. $3,156.40 07/28/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890364861
Principal investigator 1 Genentech, Inc. $7,395.00 07/19/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950725559
Principal investigator 1 ABBVIE INC. $17,920.00 07/14/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890364859
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,955.00 07/13/2022 Non-covered Recipient Entity
University Of North Carolina, Chapel Hill
Phase 2 UC POM study - A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 933190553
Principal investigator 1 Eli Lilly and Company $290.00 07/12/2022 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
MULTICENTER, OPEN-LABEL, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF SUBCUTANEOUS IXEKIZUMAB WITH ADALIMUMAB REFERENCE ARM, IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS SUBTYPES OF ENTHESITIS-RELATED ARTHRITIS (INCLUDING JUVENILE-ONSET ANKYLOSING SPONDYLITIS) AND JUVENILE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 917817535
Principal investigator 1 Genentech, Inc. $898.20 07/12/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950725563
Principal investigator 1 Roche Products Limited $819.00 07/12/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950725569
Principal investigator 1 Roche Products Limited $1,644.00 07/07/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950725575
Principal investigator 1 ABBVIE INC. $6,649.60 06/27/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890363631
Principal investigator 1 ABBVIE INC. $11,985.00 06/16/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890363629
Principal investigator 1 Roche Products Limited $1,290.60 06/09/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950742183
Principal investigator 1 Genentech, Inc. $1,008.00 06/07/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950742189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,064.00 06/03/2022 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 937169429
Principal investigator 1 ABBVIE INC. $1,465.60 06/01/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890363633
Principal investigator 1 Genentech, Inc. $188.10 05/19/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950742195
Principal investigator 1 Roche Products Limited $16,472.01 05/19/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 950742201
Principal investigator 1 Roche Products Limited $1,492.00 05/17/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 950742205
Principal investigator 1 Genentech, Inc. $2,228.40 05/12/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950742211
Principal investigator 1 Roche Products Limited $3,234.60 05/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950742217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,064.00 05/06/2022 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 937167879
Principal investigator 1 ABBVIE INC. $3,000.00 04/28/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) No dispute reported 06/30/2026 890362261
Principal investigator 1 Novo Nordisk Inc $19,098.28 04/18/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
Efficacy of GLP-1 receptor agonist therapy in patients with an ileal -pouch anal anastomosis (IPAA) No dispute reported 06/30/2026 897304895
Principal investigator 1 Roche Products Limited $1,513.80 04/14/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950742223
Principal investigator 1 Roche Products Limited $750.00 04/05/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950742227
Principal investigator 1 ABBVIE INC. $1,350.40 03/30/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease No dispute reported 06/30/2026 890361341
Principal investigator 1 Genentech, Inc. $2,250.00 03/22/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950749999
Principal investigator 1 Genentech, Inc. $982.80 03/08/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950750011
Principal investigator 1 Roche Products Limited $1,053.00 03/08/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950750005
Principal investigator 1 ABBVIE INC. $1,350.40 02/28/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohns Disease No dispute reported 06/30/2026 889778597
Principal investigator 1 Novo Nordisk Inc $275.50 02/22/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
Efficacy of GLP-1 receptor agonist therapy in patients with an ileal -pouch anal anastomosis (IPAA) No dispute reported 06/30/2026 897304887
Principal investigator 1 Genentech, Inc. $1,109.70 02/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 950750017
Principal investigator 1 Novo Nordisk Inc $10,162.50 02/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
Efficacy of GLP-1 receptor agonist therapy in patients with an ileal -pouch anal anastomosis (IPAA) No dispute reported 06/30/2026 897304891
Principal investigator 1 Roche Products Limited $460.80 02/10/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950750021
Principal investigator 1 PFIZER INC. $154,002.00 01/31/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY OF TOFACITINIB IN PATIENTS WITH UC No dispute reported 06/30/2026 949741941
Principal investigator 1 Roche Products Limited $1,053.00 01/11/2022 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 950750027